Published in

Oxford University Press, Open Forum Infectious Diseases, 8(9), 2022

DOI: 10.1093/ofid/ofac349

Links

Tools

Export citation

Search in Google Scholar

Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections

Journal article published in 2022 by Brian Grunau ORCID, Janessa Tom, Michael Asamoah-Boaheng, Sheila F. O’Brien, Steven J. Drews, Sadaf Sediqi, Pascal M. Lavoie, Vilte Barakauskas, David M. Goldfarb
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
White circle
Published version: policy unclear
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Nucleocapsid serological assay sensitivity to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections among vaccinees and for Omicron cases is unclear. In this prospective study, the Elecsys nucleocapsid assay was 89% sensitive in identifying SARS-CoV-2 infections 14–607 days pre–blood collection. Sensitivity was similar when comparing by vaccination status, and in Omicron (vs pre-Omicron) cases.